Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUINORA vs CARDRASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Treatment of atrial fibrillation and flutter,Ventricular arrhythmias,Off-label: Management of malaria (as quinine derivative)
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
Adult: 100 mg orally twice daily.
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4; also metabolized by CYP2C9 and CYP2E1. Active metabolites include 3-hydroxyquinidine. Renal excretion of unchanged drug accounts for 10-20% of clearance.
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
90-95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
2.5-3.5 L/kg; extensive tissue distribution with high affinity for cardiac muscle.
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
Oral: ~70-80% (first-pass metabolism reduces bioavailability; food may decrease rate but not extent).
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: avoid use or prolong dosing interval to every 8 hours.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 60 mg/kg/day.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
Start at lowest effective dose; consider 325 mg every 6-8 hours due to increased risk of accumulation.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
May cause potentially fatal ventricular arrhythmias (e.g., torsades de pointes) due to QT prolongation. Reserve for patients with life-threatening arrhythmias. Monitor ECG and serum electrolytes. Discontinue if QT interval >50% baseline or QRS duration increases >25%.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
May cause cinchonism (tinnitus, headache, visual disturbances). Risk of QT prolongation and torsades de pointes, especially in patients with hypokalemia, bradycardia, or structural heart disease. Hemolytic anemia may occur in G6PD deficiency. Can exacerbate heart failure due to negative inotropic effects. Drug interactions: hepatic enzyme inducers/inhibitors, other QT-prolonging drugs.
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
History of QT prolongation or torsades de pointes with quinidine. Myasthenia gravis (due to anticholinergic effects). Complete AV block without pacemaker. Known hypersensitivity (including thrombocytopenia). Major contraindication in malaria caused by Plasmodium falciparum with severe adverse reactions.
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
Grapefruit juice increases quinidine levels; avoid concurrent use. Food does not affect absorption significantly; take with or without food. High-fat meals may delay absorption.
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may cause premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
Excreted into breast milk; M/P ratio unknown. Due to risk of serious adverse reactions in nursing infants including kernicterus in neonates with G6PD deficiency, contraindicated during breastfeeding.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
Increased volume of distribution and renal clearance during pregnancy may require dose increase; therapeutic drug monitoring recommended to maintain efficacy.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
Quinora (quinidine) is a class Ia antiarrhythmic; monitor for QT prolongation and torsades de pointes. Use with caution in heart failure, renal impairment, and hepatic dysfunction. Check serum potassium and magnesium levels before initiation. Watch for cinchonism (tinnitus, headache, blurred vision) at high doses. Avoid use with other QT-prolonging drugs. Therapeutic drug monitoring is recommended (target 2-6 mcg/m L).
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
Take exactly as prescribed; do not skip doses or double up if missed.,Report any signs of allergic reaction (rash, fever, difficulty breathing) or unusual bleeding/bruising.,Avoid grapefruit juice as it may increase quinidine levels.,Contact your doctor if you experience dizziness, fainting, or palpitations.,Do not stop abruptly; taper as directed to avoid rebound arrhythmias.,Tell all healthcare providers you are taking quinidine.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUINORA vs CARDRASE, answered by our medical review team.
QUINORA is a Antiarrhythmic Agent that works by Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.. CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUINORA and CARDRASE depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUINORA is: 325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.. The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUINORA and CARDRASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUINORA is classified as Category C. In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exp. CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.